Reckitt's OTC Sales Slide 40% In 'Exceptionally Weak' Cold & Flu Season
Reckitt reports major drop in OTC sales in Q1 as the cold and flu season was almost wiped out by social distancing measures related to COVID-19. CEO Laxman Narasimhan reveals he has seen green shoots in certain markets where restrictions have started to relax, insisting "there is no question flu will come back."
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Consumers' significant shift to buying more health products online likely is a permanent trend, says RB CEO Laxman Narasimhan. A 37.4% jump in North America on health product stockpiling drove 13.6% growth in global health business sales.
Sweden's BioGaia is looking to capitalize on growing momentum in the US probiotics market with a number of launches. The firm's recent US growth helped to offset falling sales in its more established European markets during the first quarter.